Fibroblast growth factor 21 predicts arteriovenous fistula functional patency loss and mortality in patients undergoing maintenance hemodialysis

References

• Mousavi SF, Sepehri MM, Khasha R, et al. Improving vascular access creation among hemodialysis patients: an agent-based modeling and simulation approach. Artif Intell Med. 2022;126:1. doi: 10.1016/j.artmed.2022.102253.
   Web of Science ®Google Scholar
• Lok CE, Huber TS, Lee T, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020;75(4):S1–10. doi: 10.1053/j.ajkd.2019.12.001.
   PubMed Web of Science ®Google Scholar
• Lawson JH, Niklason LE, Roy-Chaudhury P. Challenges and novel therapies for vascular access in haemodialysis. Nat Rev Nephrol. 2020;16(10):586–602. doi: 10.1038/s41581-020-0333-2.
   PubMed Web of Science ®Google Scholar
• Barcena AJR, Perez JVD, Liu O, et al. Localized peri­vascular therapeutic approaches to inhibit venous neo­intimal hyperplasia in arteriovenous fistula access for hemodialysis use. Biomolecules. 2022;12(10):1367. doi: 10.3390/biom12101367.
   PubMed Web of Science ®Google Scholar
• Riella MC, Roy-Chaudhury P. Vascular access in haemodialysis: strengthening the achilles’ heel. Nat Rev Nephrol. 2013;9(6):348–357. doi: 10.1038/nrneph.2013.76.
   PubMed Web of Science ®Google Scholar
• Vazquez-Padron RI, Allon M. New insights into dialysis vascular access: impact of preexisting arterial and venous pathology on AVF and AVG outcomes. Clin J Am Soc Nephrol. 2016;11(8):1495–1503. doi: 10.2215/CJN.01860216.
   PubMed Web of Science ®Google Scholar
• Yang M, Liu C, Jiang N, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne). 2023;14:1220426. doi: 10.3389/fendo.2023.1220426.
   PubMedGoogle Scholar
• Li Q, Zhang Y, Ding D, et al. Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease. J Clin Endocrinol Metab. 2016;101(12):4886–4894. doi: 10.1210/jc.2016-2308.
   PubMed Web of Science ®Google Scholar
• Tan H, Yue T, Chen Z, et al. Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. Int J Biol Sci. 2023;19(1):66–88. doi: 10.7150/ijbs.73936.
   PubMed Web of Science ®Google Scholar
• Yan F, Yuan L, Yang F, et al. Emerging roles of fibroblast growth factor 21 in critical disease. Front Cardiovasc Med. 2022;9:1053997. doi: 10.3389/fcvm.2022.1053997.
   PubMed Web of Science ®Google Scholar
• Li X, Shen H, Zhou T, et al. Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS? Respir Res. 2021;22(1):182. doi: 10.1186/s12931-021-01778-w.
   PubMed Web of Science ®Google Scholar
• Jiang L, Yin Q, Yang M, et al. Fibroblast growth factor 21 predicts and promotes vascular calcification in haemodialysis patients. Kidney Dis (Basel). 2021;7(3):227–240. doi: 10.1159/000512750.
   PubMed Web of Science ®Google Scholar
• Aitken E, Kearns R, Gaianu L, et al. Long-Term functional patency and cost-effectiveness of arteriovenous fistula creation under regional anesthesia: a randomized controlled trial. J Am Soc Nephrol. 2020;31(8):1871–1882. doi: 10.1681/ASN.2019111209.
   PubMed Web of Science ®Google Scholar
• Feng S, Peden EK, Guo Q, et al. Downregulation of the endothelial histone demethylase JMJD3 is associated with neointimal hyperplasia of arteriovenous fistulas in kidney failure. J Biol Chem. 2022;298(5):101816. doi: 10.1016/j.jbc.2022.101816.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Lai YJ, Tung YC, et al. Osteopontin mediation of disturbed flow-induced endothelial mesenchymal transition through CD44 is a novel mechanism of neointimal hyperplasia in arteriovenous fistulae for hemodialysis access. Kidney Int. 2023;103(4):702–718. doi: 10.1016/j.kint.2022.12.022.
   PubMed Web of Science ®Google Scholar
• Ruan L, Yao X, Li W, et al. Effect of galectin-3 in the pathogenesis of arteriovenous fistula stenosis formation. Ren Fail. 2021;43(1):566–576. doi: 10.1080/0886022X.2021.1902822.
   PubMed Web of Science ®Google Scholar
• Baek J, Lee H, Yang T, et al. Plasma interleukin-6 level predicts the risk of arteriovenous fistula dysfunction in patients undergoing maintenance hemodialysis. J Pers Med. 2023;13(1):151. doi: 10.3390/jpm13010151.
   Web of Science ®Google Scholar
• Chen Z, Yang L, Liu Y, et al. The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol. 2022;13:1089214. doi: 10.3389/fphar.2022.1089214.
   PubMed Web of Science ®Google Scholar
• Jin L, Geng L, Ying L, et al. FGF21-Sirtuin 3 axis confers the protective effects of exercise against diabetic cardiomyopathy by governing mitochondrial integrity. Circulation. 2022;146(20):1537–1557. doi: 10.1161/CIRCULATIONAHA.122.059631.
   PubMed Web of Science ®Google Scholar
• Li X, Zhu Z, Zhou T, et al. Early increases in serum FGF21 levels predict mortality of septic patients. Cytokine. 2018;111:428–433. doi: 10.1016/j.cyto.2018.05.020.
   PubMed Web of Science ®Google Scholar
• Yong G, Li L, Hu S. Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis. Ren Fail. 2023;45(1):2179336.
   PubMed Web of Science ®Google Scholar
• Ong KL, Hui N, Januszewski AS, et al. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the treating to new targets [TNT] study). Metabolism. 2019;93:93–99. doi: 10.1016/j.metabol.2018.11.006.
   PubMed Web of Science ®Google Scholar
• Wu L, Qian L, Zhang L, et al. Fibroblast growth factor 21 is related to atherosclerosis independent of nonalcoholic fatty liver disease and predicts atherosclerotic cardiovascular events. J Am Heart Assoc. 2020;9(11):e015226. doi: 10.1161/JAHA.119.015226.
   PubMed Web of Science ®Google Scholar
• Lee T, Qian J, Thamer M, et al. Gender disparities in vascular access surgical outcomes in elderly hemodialysis patients[J]. Am J Nephrol. 2019;49(1):11–19. doi: 10.1159/000495261.
   PubMed Web of Science ®Google Scholar
• Gardezi AI, Karim MS, Rosenberg JE, et al. Markers of mineral metabolism and vascular access complications: the choices for healthy outcomes in caring for ESRD (CHOICE) study[J]. Hemodial Int. 2020;24(1):43–51. doi: 10.1111/hdi.12798.
   PubMed Web of Science ®Google Scholar
• Yap Y-S, Ting K-T, Chi W-C, et al. Aortic arch calcification as a predictor of repeated arteriovenous fistula failure within 1-Year in hemodialysis patients[J]. Biomed Res Int. 2017;2017:6728437–6728439. doi: 10.1155/2017/6728437.
   PubMed Web of Science ®Google Scholar
• Li M, Jiang LQ, Zhang MY, et al. Elevated serum FGF21 is an independent predictor for adverse events in hemodialysis patients from two large centers: a prospective cohort study. Ren Fail. 2023;45(2):2256414.
   PubMed Web of Science ®Google Scholar
• Chiu L-T, Wang C-H, Lin Y-L, et al. Association of serum fibroblast growth factor 21 levels with skeletal muscle mass and mortality in chronic hemodialysis patients. J Formos Med Assoc. 2022;121(12):2481–2489. doi: 10.1016/j.jfma.2022.05.007.
   PubMed Web of Science ®Google Scholar
• Khan YH, Sarriff A, Adnan AS, et al. Blood pressure and mortality in hemodialysis patients: a systematic review of an ongoing debate. Ther Apher Dial. 2016;20(5):453–461. doi: 10.1111/1744-9987.12406.
   PubMed Web of Science ®Google Scholar
• Yap Y-S, Chi W-C, Lin C-H, et al. Association of early failure of arteriovenous fistula with mortality in hemodialysis patients. Sci Rep. 2021;11(1):5699. doi: 10.1038/s41598-021-85267-6.
   PubMed Web of Science ®Google Scholar
• Geerse DA, Van Berkel M, Vogels S, et al. Moderate elevations of high-sensitivity cardiac troponin I and B-type natriuretic peptide in chronic hemodialysis patients are associated with mortality[J]. Clin Chem Lab Med. 2013;51(6):1321–1328. doi: 10.1515/cclm-2012-0305.
   PubMed Web of Science ®Google Scholar
• Yao D, He Q, Sun J, et al. FGF21 attenuates hypoxia‑induced dysfunction and inflammation in HPAECs via the microRNA‑27b‑mediated PPARγ pathway. Int J Mol Med. 2021;47(6):116. doi: 10.3892/ijmm.2021.4949.
   Web of Science ®Google Scholar
• Wei W, Li X-X, Xu M. Inhibition of vascular neointima hyperplasia by FGF21 associated with FGFR1/syk/NLRP3 inflammasome pathway in diabetic mice. Atherosclerosis. 2019;289:132–142. doi: 10.1016/j.atherosclerosis.2019.08.017.
   PubMed Web of Science ®Google Scholar
• Suassuna P, de Paula RB, Sanders-Pinheiro H, et al. Fibroblast growth factor 21 in chronic kidney disease. J Nephrol. 2019;32(3):365–377. doi: 10.1007/s40620-018-0550-y.
   PubMed Web of Science ®Google Scholar
• Salgado JV, Goes MA, Salgado Filho N. FGF21 and chronic kidney disease. Metabolism. 2021;118:154738. doi: 10.1016/j.metabol.2021.154738.
   PubMed Web of Science ®Google Scholar